Xin Lang Cai Jing·2025-10-14 05:28Core Viewpoint - WuXi AppTec's stock price has experienced significant fluctuations, with a year-to-date increase of 83.13% but a recent decline of 7.17% over the past five trading days [1] Company Overview - WuXi AppTec, established on December 1, 2000, and listed on May 8, 2018, operates in the pharmaceutical industry, providing comprehensive services in drug discovery, development, and manufacturing [1] - The company's revenue composition includes: 78.37% from chemical business, 12.93% from testing services, 6.02% from biological services, 1.90% from other supplementary services, and 0.79% from miscellaneous [1] Financial Performance - For the first half of 2025, WuXi AppTec reported revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion yuan, reflecting a substantial growth of 101.92% [2] - The company has distributed a total of 14.06 billion yuan in dividends since its A-share listing, with 10.406 billion yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, WuXi AppTec had 235,500 shareholders, with the Hong Kong Central Clearing Limited being the second-largest shareholder, holding 302 million shares, an increase of 5.603 million shares from the previous period [2][3] - Other notable shareholders include Huaxia SSE 50 ETF and China Europe Medical Health Mixed A, with varying changes in their holdings [3]